Recent progress in the biology of multiple myeloma and future directions in the treatment

Hematology and Cell Therapy

Volumn 40, Issue 2, 1998, Pages 45-61

  Pico, J L ^a   Castagna, L ^a   Bourhis, J H ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Biology; Multiple myeloma; Pathogeny; Prognostic factors; Treatment

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BLEOMYCIN; CD34 ANTIGEN; CLODRONIC ACID; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; ETIDRONIC ACID; ETOPOSIDE; INTERLEUKIN 6; LOMUSTINE; MELPHALAN; METHOTREXATE; PAMIDRONIC ACID; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; VINCRISTINE;

ANEMIA; ANTIBIOTIC PROPHYLAXIS; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE ATROPHY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL SELECTION; CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE MYELOMA; NONHUMAN; PLASMA CELL; PROGNOSIS; REVIEW;

BONE MARROW CELLS; COMBINED MODALITY THERAPY; CYTOKINES; HUMANS; IMMUNE SYSTEM; MULTIPLE MYELOMA; PLASMA CELLS; RANDOMIZED CONTROLLED TRIALS; STROMAL CELLS;

EID: 0031970334     PISSN: 12693286     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (176)

1. Aapro MS, Alberts DS, Salmon SE (1983) Interaction of human leucocytes interferon with vinca alkaloids and other chemothe-rapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol 10: 161-166
2. Abramson N, Lurie P, Mietlowski WL, et al. (1982) Phase III study of intermittent carmustine (BCNU), cyclophosphamide and prednisone versus intermittent melphalan and prednisone in myeloma. Cancer Treat Rep 66: 1273-1277
3. Alexanian R, Dimopoulos M (1994) The treatment of multiple myeloma. N Engl J Med 330: 484-489
4. Alexanian R, Dreicer R (1984) Chemotherapy for multiple myeloma. Cancer 53: 583-588
5. Attall M, Harousseau JL, Stoppa AM, et al. (1996) A prospective, randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335: 91-97
6. Attal M, Payen C, Facon T, et al. (1997) High-dose therapy in multiple myeloma: the experience of the "Intergroupe Français du Myeloma" (IFM). In: Syllabus VI International Workshop on Multiple myeloma. Boston, Massachusetts, USA
7. Bakkus MHC, Van Riet I, Van Camp B, et al. (1994) Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Haematol 87: 68-74
8. Balkwill FR, Moodey EM (1985) Positive interactions between human interferons and cyclophosphamide or adrimycin in a human tumor model system. Cancer Res 44: 906-908
9. Baltz B, Gray P, Wagner B, et al. (1992) Reconstitution of high LAK activity after autologous bone marrow transplantation is a poor prognostic factor for patients with multiple myeloma (abstract). Blood 80: 122a
10. Barker HF, Ball J, Drew M, et al. (1993) The role of adhesion molecules in multiple myeloma. Leuk Lymphoma 8: 189-196
11. Barlogie B, Jagannath S, Vesole DH, et al. (1997) Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89: 789-793
12. Bataille R, Chappard D, Marcelli C, et al. (1991) The recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 88: 62-66
13. Bataille R, Manolagas SC, Berenson JR (1997) Pathogenesis and management of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 11: 349-361
14. Bataille R, Boccadoro M, Klein B, et al. (1992) C-reactive protein and serum b2-microglobulin produce a simple and powerful myeloma staging system. Blood 80: 733-737
15. Bataille R, Barlogie B, Lu ZY, et al. (1995) Biologic effects of anti-interleukine-6 murine monoclonal antibody in advanced multiple myeloma. Blood 86: 685-691
16. Belch AR, Bergsagel DE, Wilson K, et al. (1991) Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 9: 1397-1402
17. Berenson JR, Lichtenstein A, Porter L, et al. (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334: 488-493
18. Berenson JR (1997) Biphosphonates in multiple myeloma. Cancer 80: 1661-1667
19. Bergenbrant S, Österborg A, Holm G, et al. (1991) Anti-idiotypic antibodies in patients with monoclonal gammopathies: relation to the tumour load. Br J Haematol 78: 66-70
20. Bergenbrant S, Yi Q, Österborg A, et al. (1996) Modulation of anti-idiotypic immune response by immunisation with autologous M-component protein in multiple myeloma patients. Br J Haematol 92: 840-846
21. Bergsagel DE, Bailey AJ, Langley GR, et al. (1979) The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 301: 743-748
22. Bergsagel PL, Masellis Smith A, Szczepek A, et al. (1995) In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56 and monotypic immunoglobulin light chain. Blood 85: 436-447
23. Bertz H, Burger JA, Kunzmann R, et al. (1997) Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia 11: 282-283
24. Billadeau D, Quam L, Thomas W, et al. (1992) Detection and quantitation of malignant cells in peripheral blood of multiple myeloma patients. Blood 80: 1818-1824
25. Billadeau D, Van Ness B, Kimlinger T, et al. (1996) Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smouldering multiple myeloma and active myeloma. Blood 88: 289-296
26. Bird JM, Bloxham D, Samson D, et al. (1994) Molecular detection of clonally cells in peripheral blood progenitor cell harvests from multiple myeloma patients. Br J Haematol 88: 110-116
27. Björkstrand B, Ljungman P, Bird JM, et al. (1995) Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remission in multiple myeloma. Bone Marrow Transplant 15: 367-371
28. Björkstrand B, Ljungman P, Svensson H, et al. (1996) Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 88: 4711-4715
29. Boccadoro M, Marmont F, Tribalto M, et al. (1991) Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 9: 444-448
30. + T cells confer idiotype-specific resistance in the absence of antibodies. Eur J Immunol 25: 3079-3086
31. + T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol 26: 2671-2679
32. Boonekamp PM, van der Wee-Pals LJA, van Wijk-Lennep MML, et al. (1986) Two modes of action of biphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1: 27-39
33. Bottomly K, Mosier DE (1989) Antigen specific helper T cells required for dominant idiotype expression are not H-2 restricted. J Exp Med 154: 411-421
34. + selected peripheral hematopoietic progenitors (PHP) leads to durable engraftment in multiple myeloma patients following myeloablative intensive therapy. Blood 84 [Suppl 1]: 209a
35. Brenning G (1985) The in vitro effect of leukocyte alpha-inteferon on human myeloma cells in a semi-solid agar system. Scand J Haematol 35: 178-185
36. Calasanz MJ, Cigudosa JC, Odero MD, et al. (1997) Hypodiploidy and 22q11 rearrengements at diagnosis are associated with a poor prognosis in patients with multiple myeloma. Br J Haematol 98: 418-425
37. Cazzola M, Ponchio L, Beguin Y, et al. (1992) Subcutaneous eythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood 79: 27-37
38. Cazzola M, Messinger D, Battistel V, et al. (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin lymphoma: dose finding and identification of predictors of response. Blood 86: 4446-4453
39. Chapel HM, Lee M, Hargreaves R, et al. (1994) Randomised trial of intravenous immune globulin as prophylaxis against infection in plateau-phase multiple myeloma. Lancet 343: 1059-1063
40. Chauhan D, Kharbanda S, Ogata A, et al. (1997) Interleukin-6 inhibits Fas induced apoptosis and SAP kinase activation in multiple myeloma cells. Blood 89: 227-234
41. Chen BJ, Epstein J (1996) Circulating clonal mymphocytes in multiple myeloma constitute a minor subpopulation of B cells. Blood 87: 1972-1976
42. Cohen HJ, Silberman HR, Tornyos K, Bartolucci AA (1984) Comparison of two long-term chemotherapy regimens with or without agents to modify skeletal repair, in multiple myeloma. Blood 63: 639-648
43. Condon C, Watkins SC, Celluzzi CM, et al. (1996) DNA-based immunistion by in vivo transfection of dendritic cells. Nature Med 2: 1122-1128
44. Cooper MR, McIntyre OR, Propert KJ (1986) Single, sequential, and multiple alkylating agents in therapy for multiple myeloma: a CALGB study. J Clin Oncol 4: 1331-1339
45. Corradini P, Boccadoro M, Voena M, et al. (1993) Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ-joined to Cμ sequence in IgG and IgA-secreting multiple myeloma. J Exp Med 178: 1091-1096
46. Crucian BE, Moscinski LC, Androlewicz M, et al. (1997) Assessment of intracellular TAP-1 and TAP-2 in conjunction with surface MHC class I in plasma cells from patients with multiple myeloma. Br J Haematol 98: 426-432
47. Dimoulpoulos MA, Moulopoulos A, Smith T, et al. (1993) Risk of disease progression in asymptomatic multiple myeloma. Am J Med 94: 57-61
48. Durie BGM, Bataille R (1989) Therapeutic implication of myeloma staging. Eur J Haematol 43 [Suppl 51]: 111-116
49. Durie BGM, Stock-Novack D, Salmon SE, et al. (1990) Prognostic value of pretreatment serum β2 Microglobulin in myeloma: A Southwest Oncology Study Group. Blood 75: 823-830
50. Egle A, Villunger A, Kos M, et al. (1996) Modulation of APO-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-a2. Eur J Immunol 26: 3119-3126
51. Elsässer D, Valerius T, Repp R, et al. (1996) HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocytes colony-stimulating factor. Blood 87: 3803-3812
52. Epstein J, Hoover R, Kornbluth J, et al. (1995) Biological aspects of multiple myeloma. Clin Hematol 8: 721-734
53. Facon T, Menard JF, Michaux JL, et al. (1995) Prognostic factors in low tumor mass asymptomatic multiple myeloma. Am J Haematol 48: 71-75
54. Fermand JP, Ravaud P for the Group "Myeloma-autogreffe" (1997) High dose therapy (HDT) and autologous peripheral stem cell (PBSC) transplantation performed either as first-line therapy or as a rescue treatment: similar effect on overall survival in myeloma patients. Syllabus VI International Workshop on Multiple myeloma. Boston, Massachusetts, USA
55. Gahrton G, Tura S, Ljungman P, et al. (1995) Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 13: 1312-1322
56. Garcia-Sanz R, Gonzales M, Orfao A, et al. (1996) Analysis of natural-killer associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. Br J Haematol 93: 81-88
57. Garton JP, Gertz MA, Witzig TE, et al. (1995) Epoetin alfa for the treatment of the anemia of multiple myeloma. Arch Intern Med 155: 2069-2074
58. Gazitt Y, Reading CC, Hoffman R, et al. (1995) Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells. Blood 86: 381-389
59. Giralt S, Estey E, Albitar M, et al. (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89: 4531-4536
60. Gonzalez M, San Miguel JF, Gascon A, et al. (1992) Increased expression of natural-killer-associated and activation antigens in multiple myeloma. Am J Haematol 39: 84-89
61. Gregory WM, Richards MA, Malpas JS (1992) Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 10: 334-342
62. Greipp PR, Lust JA, O'Fallon WN, et al. (1993) Plasma cell labelling index and b2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in myltiple myeloma. Blood 81: 3382-3387
63. Hansen OP, Clausen NAT, Drivsholm A, et al. (1985) Phase III study of intermittent 5-drug regimen (VBCMP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis. Scand J Haematol 35: 518-524
64. Harley JB, Pajak TF, McIntyre OR, et al. (1979) Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB. Blood 54: 13-21
65. Harousseau JL, Milpied N, Laporte JP, et al. (1992) Double-intensive therapy in high-risk multiple myeloma. Blood 79: 2827-2833
66. Helfrich MH, Livingstone E, Franklin IM, et al. (1997) Expression of adhesion molecules in malignant plasma cells in multiple myeloma: comparison with normal plamsa cells and functional signifiance. Blood Rev 11: 28-38
67. Herrmann F, Andreeff M, Gruss HJ, et al. (1991) Interleukin-4 inhibits growth of multiple myeloms by suppressing interleukin-6 expression. Blood 78: 2070-2074
68. Hjorth M, Hellquist L, Holmberg E, et al. (1993) Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - a randomised study. Eur J Haematol 50: 95-102
69. Hjorth M, Hellquist L, Holmberg E, et al. (1990) Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. Br J Haematol 74: 185-191
70. + positive haemopoietic cells: biology and clinical applications. Blood Rev 8: 113-124
71. Hoover RG, Lary C, Page R, et al. (1995) Autoregulatory circuits in myeloma. Tumour cell cytotoxicity mediated by soluble CD16. J Clin Invest 95: 241-247
72. Hsu FJ, Benike C, Fagnoni F, et al. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 2: 52-58
73. Huang YW, Richardson JA, Vitetta ES (1995) Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells. Cancer Res 55: 610
74. Hughes DE, Wright KR, Uy H, et al. (1995) Biphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10: 1478-1487
75. Isaksson E, Björkholm M, Holm G, et al. (1996) Blood clonal-B cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): association with malignant transformation. Br J Haematol 92: 71-76
76. Janeway CJ, Sakato N, Eisen HN (1975) Recognition of immunoglobulin idiotypes by thymus-derived lymphocytes. Proc Natl Acad Sci USA 72: 2357-2360
77. Jerne NK (1974) Towards a network theory of the immune system. Ann Immunol 125C: 373-389
78. Jourdan M, Zhang XG, Portier M, et al. (1991) Alpha Interferon induces autocrine production of IL-6 in myeloma cell lines. J Immunol 147: 4402-4407
79. Jung A, Bornand J, Mermillod B, et al. (1984) Inhibition by diphosphonates of bone resorption induced by the Walker tumour of the rat. Cancer Res 44: 3007-3011
80. Kay NE, Leong T, Kyle RA, et al. (1997) Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial. Blood 90: 340-345
81. Kellihan MJ, Mangino PD (1992) Pamidronate. Ann Pharmacother 26: 1262-1269
82. Kildahl-Andersen O, Bjark P, Bondevk A, et al. (1988) Multiple myeloma in central and northern Norway 1981-1982: a follow-up study of a randomised clinical trial of a 5-drug combination therapy versus standard therapy. Eur J Haematol 41: 47-51
83. Kimlinger T, Witzig TE (1997) Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma. Bone Marrow Transplant 19: 553-556
84. Klein B, Zhang XG, Jourdan M, et al. (1989) Paracrine rather than tocrine regulation of myeloma-cell growth and proliferation by interleukin-6. Blood 73: 517-526
85. Klein B (1996) Growth factors in the pathogenesis of multiple myeloma. In: Gahrton G, Dune BGM (eds) Multiple Myeloma, Arnold, London, pp 73-82
86. Klein U, Küppers R, Rajewsky K (1997) Evidence for a large compartment of IgM-expressing memory B-cells in humans. Blood 89: 1288-1298
87. Kobayashi M, Tanaka J, Imamura M, et al. (1993) Up-regulation of IL-6 receptor on a plasma cell leukemia cell line which proliferate dependency on both IL-3 and IL-6. Br J Haematol 83: 535-538
88. Kolb HJ, Mittermuller J, Clemm C, et al. (1990) Donor lymphocyte transfusion for treatment of chronic myelogenous leukemia in marrow transplant patients. Blood 76: 2462-2465
89. Kornbluth J, Snead T, Page R, et al. (1993) Effective treatment of established human myeloma tumours in SCID mice with human natural killer cells and interleukins (IL-2 and IL-4) (abstract). Blood 82: 263a
90. Kornbluth J (1995) Potential role of CD28-B7 interactions in the growth of myeloma plasma cells. Curr Top Microbiol Immunol 194: 43-49
91. Kozak ST, Rizzoli R, Trechsel U, et al. (1987) Effect of a single injection of two new biphosphonates on the hypercalcemia and hypercalciuria induced by Walker carcinoma 256/B in thyroparathyroidectomized rats. Cancer Res 47: 6193-6197
92. Kuipers I, Weghuis O, Nardini E (1997) Fish on metaphases and halo-DNA visualises the ubiquitous presence and localization of breakpoints in 14q32.2 chromosomal rearrangements in myeloma lines. Syllabus Vl International Workshop on Multiple myeloma. Boston, Massachusetts, USA
93. Kwald LW, Campbell MJ, Czerwinski DK, et al. (1992) Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumours. N Engl J Med 327: 1209-1215
94. Kwak LW, Taub DD, Duffey PL, et al. (1995) Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 345: 1016-1020
95. Lahtinen R, Laasko M, Palva I, et al. (1992) Randomised, placebocontrolled multicentre trial of clodronate in multiple myeloma. Lancet 340: 1420-1423
96. Landowski TH, Qu N, Buyuksal I, et al. (1997) Blood 90: 4266-4270
97. Lauritzsen GF, Weiss S, Bogen B (1993) Anti-tumour activity of idiotype-specific, MHC-restricted Th1 and Th2 clones in vitro and in vivo. Scand J Immunol 37: 77-85
98. + T cells in tumour resistence against major histocompatibility complex class II molecule negative plasmocytoma cells. Cell Immunol 148: 177-188
99. + cells to remove circulating tumour cells. Blood 87: 1625-1634
100. Lokhorst HM, Lamme T, de Smet M, et al. (1994) Primary tumour cells of myeloma patients induce interleukin-6 secretion in long term bone marrow culture. Blood 84: 2269-2277
101. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. (1997) Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 90: 4206-4211
102. Ludwig H, Nachbaur DM, Fritz E (1991) Interleukin-6 is a prognostic factor in multiple myeloma. Blood 77: 2794-2795
103. Ludwig H, Cohen AM, Polliack A, et al. (1995) Interferon-alpha r induction and maintenance in multiple myeloma: results of two multicenter randomised trials and summary of others studies. Ann Oncol 6: 467-476
104. Ludwig H, Fritz E, Kotzman H, et al. (1990) Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322: 1693-1699
105. MacKenzie J, Sheldon J, Cook G, et al. (1997) HHV-8 and multiple myeloma in UK. Lancet 350: 1144-1145
106. Marcelin AG, Dupin N, Bouscary D, et al. (1997) HHV-8 and multiple myeloma in France (letter). Lancet 350: 1144
107. Mariette X, Fermand JP, Brouet JC (1994) Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy. Bone Marrow Transplant 14: 47-50
108. Marmont AM, Horowitz MM, Gale RP, et al. (1991) T-cell depletion of HLA-identical transplants in leukemia. Blood 78: 2120-2130
109. Martin PJ, Kernan NA (1997) T-cell depletion for GVHD prevention in humans. In: Ferrara JLM, Deeg HJ, Burakoff SJ (eds) Graft-vs-host disease. Dekker, New York, pp 615-637
110. Massaia M, Borrione P, Attisano C, et al. (1995) Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. Blood 85: 3679-3687
111. Mayordomo JI, Zorina T, Storkus WJ, et al. (1995) Bone marrowderived dentritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med 1: 1297-1302
112. McCloskey EV, MacLennan ICM, Drayson M, et al. (1996) Effect of clodronate on morbidity and mortality in myelomatosis (abstract). Ann Oncol 7 [Suppl 5]: 4120a
113. Mittelmen M, Zeidam A (1996) R-HuEPO for the treatment of anaemia associated with multiple myeloma. Erythropoiesis 7: 91-97
114. Moore PS, Boshoff C, Weiss RA, et al. (1996) Molecular mimicry of the human cytokines response pathway genes by KSHV. Science 274: 1739-1744
115. + T cells in patients with multiple myeloma and paraproteinemia. Blood 87: 3297-3306
116. Munshi NC (1997) Immunoregulatory mechanisms in multiple myeloma. Hematol Oncol Clin North Am 11: 51-69
117. Myltenyi S (1994) Magnetic approaches to cell separation. In: Morstyn G Sheridan W (eds) Cell therapy. Cambridge, pp 213-220
118. Oken MM, Pomeroy C, Weisdorf D, et al. (1996) Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 100: 624-628
119. Omedé P, Boccadoro M, Fusaro A, et al. (1993) Multiple myeloma: "early" plasma cells phenotype identifies patients with aggressive biological and clinical characteristics. Br J Haematol 85: 504-513
120. O'Reilly RJ, Kernan N, Cunningham I (1988) Soyben lectin agglutination and E-Rosette depletion for removal of T-cells from HLA-identical and non-identical marrow graft administred for the treatment of leukemia. In: Martelli F, Grignani F, Reisner Y (eds) T-cell depletion in allogenic bone marrow transplantation. ARES-SERONO Symposia, Rome, pp 123-129
121. Österborg A, Steinitz M, Lewin N, et al. (1991) Establishment of idiotype bearing B-lymphocyte clone from a patient with monoclonal gammopathy. Blood 78: 2642-2649
122. Österborg A, Ahre A, Bjorkholm M, et al. (1989) Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III A: a randomised study from MGCS. Eur J Haematol 43: 54-62
123. Österborg A, Yi Q, Bergenbrant S, et al. (1995) Idiotype-specific T cells in mutiple myeloma stage I: an evaluation by four different functional tests. Br J Haematol 89: 110-116
124. Österborg A, Masucci M, Bergenbrant S, et al. (1991) Generation of T cell clones binding F(ab')2 fragments of the idiotype immunoglobulin in patients with monoclonal gammopathy. Cancer Immunol Immunother 34: 157-162
125. Österborg A, Boogaerts MA, Cimino R, et al. (1996) Recombinant human Erythropoietin in transfusion-dependent anaemic patients with multiple myeloma and non-Hodgkin's lymphoma. A randomised multicenter study. Blood 87: 2675-2682
126. Ozaki S, Kosaka M, Wakatsuki S, et al. (1997) Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood 90: 3179-3186
127. Palva IP, Ahrenberg P, Ala-Harja K, et al. (1987) Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone: a randomised multicentre trial. Eur J Haematol 38: 50-54
128. Pardoll DM, Beckerleg AM (1995) Exposing the Immunology of naked DNA vaccines. Immunity 3: 165-169
129. Passeri G, Ulietti V, Girasole G, et al. (1994) Biphosphonates inhibit IL-6 production by human osteoblastic cells MG-63. J Bone Miner Res 9 [Suppl 1]: 230a
130. Pavlovsky S, Corrado C, Santarelli MT, et al. (1988) An update of two randomised trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three and five-drug combinations: an Argentine group for the treatment of acute leukemia study. J Clin Oncol 6: 769-775
131. Peest D, Deicher H, Clodewey R, et al. (1988) Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP. Eur J Cancer Clin Oncol 24: 1061-1067
132. Pellat-Deceunynck C, Bataille R, Robillard N, et al. (1994) Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood 84: 2597-2603
133. Perri RT, Hebbel R, Oken MM (1981) Influence of treatment and response status on infection risk in multiple myeloma. Am J Med 71: 935-938
134. Pfeiffer S, Gooding RP, Apperley JF, et al. (1997) Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similary produced from healthy donors. Br J Haematol 98: 973-982
135. Pilarski LM, Jensen GS (1992) Monoclonal circulating B cells in multiple myeloma: a continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules. Hematol Oncol Clin North Am 6: 297-322
136. Pilarski LM, Masellis-Smith A, Szczepek A, et al. (1996) Circulating clonotypic B cells in the biology of multiple myeloma: speculations on the origin of myeloma. Leuk Lymphoma 22: 375-383
137. Pilarski LM, Belch AR (1994) Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma. Blood 83: 724-736
138. Pilarski LM, Andrews EJ, Mant MJ, et al. (1986) Humoral immune deficiency in multiple myeloma patients due to compromised B-cell function. J Clin Immunol 6: 491-501
139. Pilarski LM, Szczepek A, Belch AR (1997) Deficient drug transporter function of bone marrow-localized and leukemic plasma cells in multiple myeloma. Blood 90: 3751-3759
140. Powles R, Raje N, Cunningham D, et al. (1995) Maintenance therapy for remission in myeloma with In tron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue. Stem Cells 13 [Suppl 2]: 114-117
141. Pulkki K, Pellinieme TT, Rajamaky A, et al. (1991) Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Br J Haematol 92: 370-374
142. Rettig MB, MA HJ, Vescio RA, et al. (1997) Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 276: 1851-1854
143. Reynolds JJ, Murphy H, Mühlbauer RC, et al. (1973) Inhibition by diphosphonates of bone resorption in mice and comparison with grey lethal ostepetrosis. Calcif Tissue Res 12: 59-71
144. Romani N (1994) Proliferating dendritic cell progenitors in human blood. J Exp Med 171: 159-171
145. Rosi JF, Legouffe E, Fegueux N, et al. (1997) VI International Workshop on Multiple Myeloma: 622a
146. Said JW, Rettig MR, Heppener K, et al. (1997). Localization of Kaposi's sarcoma - Associated Herpes virus in bone marrow biopsy samples from patients with multiple myeloma. Blood 90: 4278-4282
147. Salmon SE, Hant A, Bonnett JD, et al. (1983) Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1: 453-461
148. Shipman CM, Rogers MJ, Apperley JF, et al. (1997) Biphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 98: 665-672
149. + peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 86: 390-397
150. Schimitz N, Linch DC, Dreger P, et al. (1996) Randomised trial of filgrastim mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplatation in lymphoma patients. Lancet 347: 353-357
151. Sirisinsha S, Eisen HN (1971) Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc Natl Acad Sci USA 68: 3130-3135
152. Stevenson FK, Bell AJ, Cusak R, et al. (1991) Preliminary studies for an immuno-therapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood 77: 1071-1079
153. Szczepek AJ, Bergsagel PL, Axelsson L, et al. (1997) CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements. Blood 89: 1824-1833
154. Takishita M, Kosaka M (1995) Multiple myeloma: new evidence and insights from the immunoglobulin heavy chain gene and phenotypes. Leuk Lymphoma 19: 395-400
155. Tanaka H, Tanabe O, Iwato K, et al. (1989) Sensitive inhibitory effect of interferon alpha on M-protein secretion of human myeloma cells. Blood 74: 1718-1722
156. Tang DC, DeVit M, Johnston SA (1992) Genetic immunisation is a simple method for eliciting an immune response. Nature 356: 152-154
157. Taube T, Beneton MNC, McCloskey EV, et al. (1992) Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 49: 192-198
158. Teoh G, Anderson K (1997) Interaction of tumour and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am 11: 27-42
159. Tribalto M, Amadori S, Cantonetti M, et al. (1985) Treatment of mutiple myeloma: a randomised study of three different regimens. Leuk Res 9: 1043-1049
160. Tricot G, Barlogie B, Jagannath S, et al. (1995) Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86: 4250-4256
161. Tricot G, Vesole D, Jagannath S, et al. (1996) Graft-versus-myeloma effect: proof of principle. Blood 87: 1196-1198
162. Truitt RL, Johnson BD, McCabe CM, et al. (1997) Graft versus leukemia. In: Ferrara JLM, Deeg HJ, Burakoff SJ (eds) Graft-versus-host disease, Marcel Dekker, New York, p. 385-423
163. Uchiyama H, Barut BA, Mohrbacher AF, et al. (1993) Adhesion of human myeloid-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 82: 3712-3720
164. Verdonck LF, Lokhorst HM, Dekker AW, et al. (1996) Graft-versus-myeloma effect in two cases. Lancet 347: 800-801
165. Vescio RA, Hong CH, Cao J, et al. (1994) The hematopoietic stem cell antigen CD34 is not expressed on the malignant cells in multiple myeloma. Blood 84: 3283-3290
166. Vescio RA, Han EJ, Schiller GJ, et al. (1996) Quantitative comparison of multiple myeloma tumour contamination in bone marrow harvest and leukapheresis autografts. Bone Marrow Transplant 18: 103-110
167. Vesole DH, Tricot G, Jagannath S, et al. (1996) Autotransplants in multiple myeloma: what have we learned? Blood 88: 838-847
168. Villunger A, Egle A, Marschitz I, et al. (1997) Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood 90: 12-20
169. Weber DM, Dimopoulos MA, Moulopoulos LA, et al. (1997) Prognostic features of asymptomatic multiple myeloma. Br J Haematol 97: 810-814
170. Westendorf JJ, Ahmznn GJ, Armitage RJ, et al. (1994) CD40 expression in malignant plamsa cells. Role in stimulation of autocrine IL-6 secretion by human myeloma cell line. J Immunol 152: 117-128
171. Wink CS, Hill EM (1988) Dichloromethylene biphosphonate retards femoral expansion in normal and castrated adult male rats. Acta Anat 132: 321-323
172. Witzig TE, Kyle R, O'Fallon W, et al. (1994) Detection of peripheral blood plasma as a predictor of disease course in patients with smouldering multiple myeloma. Br J Hematol 87: 266-272
173. Witzig TE, Gertz MA, Lust JA, et al. (1996) Peripheral blood monoclonal cells as a predictor of survival in patients with multiple myeloma. Blood 88: 1780-1787
174. Woodruff RK, Wadsworth J, Malpas JS, et al. (1979) Clinical staging in multiple myeloma. Br J Haematol 42: 199-205
175. Yi Q, Österborg A, Bergenbrant S, et al. (1995) Idiotype-reactive T-cell subsets and tumour load in monoclonal gammopathies. Blood 86: 3043-3049
176. Yi Q, Dabadghao S, Österborg A, et al. (1997) Myeloma bone marrow plasma cells: evidence for their capacity as antigen-presenting cells. Blood 90: 1960-1967